earnings
confidence high
sentiment positive
materiality 0.55
Intelligent Bio Q1 FY27 revenue $1.39M, up 25% YoY, record; gross margin 54.5%; FDA 510(k) filed Sept 9
INTELLIGENT BIO SOLUTIONS INC.
2026-Q1 EPS reported
-$0.86
revenue$1,391,835
- Total revenue $1,391,835, up 25% year-over-year and 21% sequentially; third straight quarter above $1M and a company record, topping $1,145,802 in Q4 fiscal 2026.
- Cartridge sales $845,583 (+32% YoY, +35% sequentially), 61% of revenue; other sales $281,253 (+52% YoY), 20% of revenue.
- Gross profit $758,004, up 46% YoY; gross margin 54.5% vs 46.6% a year ago, roughly 790 bps better on manufacturing efficiencies and cartridge mix.
- Cash and equivalents $5.93M at Sept 30, 2026 vs $3.99M at June 30; 516 active customer accounts (27 added in the quarter) and 1,978 readers installed.
- FDA 510(k) submitted Sept 9, 2026 for the Intelligent Fingerprinting Drug Screening System (codeine); study showed accuracy >98%, sensitivity >94%, specificity 100% at three US sites.